Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 33Small Cell Lung Carcinoma 16Breast Neoplasms 13Sarcoma 10Carcinoma, Hepatocellular 8Esophageal Squamous Cell Carcinoma 7Lung Neoplasms 6Triple Negative Breast Neoplasms 5Ovarian Neoplasms 5Neoplasms 5Carcinoma 5Stomach Neoplasms 4Pheochromocytoma 4Pancreatic Neoplasms 4Neoplasm Metastasis 4Nasopharyngeal Carcinoma 4Esophageal Neoplasms 4Colorectal Neoplasms 4Carcinoma, Renal Cell 4Carcinoma, Ovarian Epithelial 4Thyroid Neoplasms 3Recurrence 3Paraganglioma 3NSCLC 3Glioma 3Uterine Cervical Neoplasms 2Urogenital Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Platinum-resistant Ovarian Cancer 2Ovarian Diseases 2

Interventions

anlotinib 1Radiotherapy 1Immunotherapy 1Drug Therapy 1Docetaxel 1Cisplatin 1Chemoradiotherapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Locally Advanced Non-small Cell Lung Cancer × anlotinib × Clear all
NCT05481775 2022-11-21

Evaluating Efficacy and Safety of Anlotinib Combined With Concurrent Chemoradiotherapy Followed by Consolidation Immunotherapy for Locally Advanced Non-small Cell Lung Cancer

Sun Yat-sen University

Phase 2 Withdrawn
Thoracic

Locally Advanced Non-small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡